Hill April 17, 2023
By JC Scott

The drug pricing debate in Washington has kicked back into high gear, and it is more contentious, convoluted and misguided than ever. Who’s on what team? Whose “turn” is next? And, most importantly, what is in the best interest of patients and taxpayers? These questions may sound rhetorical, but they’re questions that Congress should be asking. 

Here’s why: Navigating complex and divergent drug pricing proposals can be challenging, yet the formula for determining what should get a “yes” or “no” vote should be quite simple. First: Support bills that will lower drug prices and make prescription drugs and health benefits more affordable for patients. Second: Oppose bills that would limit options and raise costs for patients, employers and taxpayers....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Regulations
The 3 most promising uses for GenAI in healthcare
Study finds one in five US adults use multiple drugs, revealing new patterns in substance use
How Healthtech Is Transforming Elderly Care Worldwide
The (Upper) Case For Capitalizing Multiracial
Intermittent fasting vs. calorie counting: Which is more effective?

Share This Article